{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T10:26:32Z","timestamp":1794479192455,"version":"4.9.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgery"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.surg.2026.110236","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T02:37:34Z","timestamp":1778812654000},"page":"110236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Survival outcomes after neoadjuvant chemotherapy in hormone receptor\u2013positive breast cancer patients with nodal metastases: A National Cancer Database analysis"],"prefix":"10.1016","volume":"196","author":[{"given":"Siavash","family":"Bolourani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Diskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicketti","family":"Handy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal","family":"Fancher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8854-1307","authenticated-orcid":false,"given":"Janie","family":"Grumley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.surg.2026.110236_bib1","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-19-3492","article-title":"Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis","volume":"26","author":"Spring","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.surg.2026.110236_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103792","article-title":"Major pathologic response and long-term clinical benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after neoadjuvant chemotherapy","volume":"78","author":"Ji","year":"2024","journal-title":"Breast"},{"key":"10.1016\/j.surg.2026.110236_bib3","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1186\/s12957-022-02787-9","article-title":"Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China","volume":"20","author":"Guan","year":"2022","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.surg.2026.110236_bib4","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1245\/s10434-017-5898-z","article-title":"Standard pathologic features can be used to identify a subset of estrogen receptor-positive, HER2 negative patients likely to benefit from neoadjuvant chemotherapy","volume":"24","author":"Petruolo","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2026.110236_bib5","doi-asserted-by":"crossref","first-page":"213","DOI":"10.5152\/ejbh.2020.5487","article-title":"Evaluation of pathologic complete response (pCR) to neoadjuvant chemotherapy in Iranian breast cancer patients with estrogen receptor positive and HER2 negative and impact of predicting variables on pCR","volume":"16","author":"Omranipour","year":"2020","journal-title":"Eur J Breast Health"},{"key":"10.1016\/j.surg.2026.110236_bib6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.prp.2018.11.003","article-title":"Prognostic value of pathologic complete response and the alteration of breast cancer immunohistochemical biomarkers after neoadjuvant chemotherapy","volume":"215","author":"Shuai","year":"2019","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.surg.2026.110236_bib7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41523-018-0069-3","article-title":"Erratum: author correction: breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study","volume":"4","author":"Petkov","year":"2018","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.surg.2026.110236_bib8","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","article-title":"21-Gene assay to inform chemotherapy benefit in node-positive breast cancer","volume":"385","author":"Kalinsky","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.surg.2026.110236_bib9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.breast.2021.01.001","article-title":"Selection of neoadjuvant treatment based on the 21-GENE test results in luminal breast cancer","volume":"56","author":"Morales Murillo","year":"2021","journal-title":"Breast"},{"key":"10.1016\/j.surg.2026.110236_bib10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1245\/s10434-015-4603-3","article-title":"Differences in response and surgical management with neoadjuvant chemotherapy in invasive lobular versus ductal breast cancer","volume":"23","author":"Truin","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2026.110236_bib11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000537874","article-title":"Neoadjuvant chemotherapy and pathologic complete response in HR+\/HER2- breast cancer: impact of tumor Ki67 and ER status","volume":"69","author":"Akdag","year":"2024","journal-title":"Chemotherapy"},{"key":"10.1016\/j.surg.2026.110236_bib12","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241248318","article-title":"Prognostic value of pathological nodal burden after neoadjuvant chemotherapy in initially cN0-1 breast cancer patients: a dual-center, 10-year survival analysis","volume":"16","author":"Maimaitiaili","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.surg.2026.110236_bib13","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1245\/s10434-024-15393-8","article-title":"The National Cancer Database conforms to the standardized framework for registry and data quality","volume":"31","author":"Palis","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2026.110236_bib14","author":"Wickham"},{"key":"10.1016\/j.surg.2026.110236_bib15","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/bjc.2012.557","article-title":"Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas","volume":"108","author":"Delpech","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.surg.2026.110236_bib16","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1007\/s12282-024-01583-5","article-title":"Comparing survival outcomes between neoadjuvant and adjuvant chemotherapy within T2N1M0 stage hormone receptor-positive, HER2-negative breast cancer: a retrospective cohort study based on SEER database","volume":"31","author":"Shang","year":"2024","journal-title":"Breast Cancer"},{"key":"10.1016\/j.surg.2026.110236_bib17","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s10549-020-05809-w","article-title":"Use of neoadjuvant versus adjuvant chemotherapy for hormone receptor-positive breast cancer: a National Cancer Database (NCDB) study","volume":"184","author":"Zeidman","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.surg.2026.110236_bib18","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.1785","article-title":"Neoadjuvant chemotherapy or endocrine therapy for invasive ductal carcinoma of the breast with high hormone receptor positivity and human epidermal growth factor receptor 2 negativity","volume":"4","author":"Zhang","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.surg.2026.110236_bib19","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/SLA.0000000000002373","article-title":"Tumor biology and response to chemotherapy impact breast cancer-specific survival in node-positive breast cancer patients treated with neoadjuvant chemotherapy: long-term follow-up from ACOSOG Z1071 (Alliance)","volume":"266","author":"Boughey","year":"2017","journal-title":"Ann Surg"},{"key":"10.1016\/j.surg.2026.110236_bib20","doi-asserted-by":"crossref","first-page":"324","DOI":"10.29271\/jcpsp.2025.03.324","article-title":"Nomogram for predicting pathological complete response after neoadjuvant chemotherapy in operable primary breast cancer","volume":"35","author":"Lv","year":"2025","journal-title":"J Coll Physicians Surg Pak"},{"key":"10.1016\/j.surg.2026.110236_bib21","doi-asserted-by":"crossref","first-page":"102323","DOI":"10.1016\/j.ctrv.2021.102323","article-title":"Gene-expression signatures to inform neoadjuvant treatment decision in HR+\/HER2- breast cancer: available evidence and clinical implications","volume":"102","author":"Griguolo","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.surg.2026.110236_bib22","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10549-020-05989-5","article-title":"Response to neoadjuvant chemotherapy and the 21-gene Breast Recurrence Score test in young women with estrogen receptor-positive early breast cancer","volume":"186","author":"Sella","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.surg.2026.110236_bib23","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s10549-016-3837-5","article-title":"Lymphovascular invasion is an independent predictor of survival in breast cancer after neoadjuvant chemotherapy","volume":"157","author":"Liu","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.surg.2026.110236_bib24","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000011647","article-title":"Lymphovascular invasion can be better than pathologic complete response to predict prognosis in breast cancer treated with neoadjuvant chemotherapy","volume":"97","author":"Ryu","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.surg.2026.110236_bib25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10549-017-4155-2","article-title":"Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients","volume":"163","author":"Goorts","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.surg.2026.110236_bib26","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12885-022-09193-0","article-title":"Lympho-vascular invasion impacts the prognosis in breast-conserving surgery: a systematic review and meta-analysis","volume":"22","author":"Zhong","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.surg.2026.110236_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.breast.2021.11.017","article-title":"Differences in sensitivity to neoadjuvant chemotherapy among invasive lobular and ductal carcinoma of the breast and implications on surgery\u2014a systematic review and meta-analysis","volume":"61","author":"O\u2019Connor","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.surg.2026.110236_bib28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41523-019-0125-7","article-title":"Success rates of re-excision after positive margins for invasive lobular carcinoma of the breast","volume":"5","author":"Piper","year":"2019","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.surg.2026.110236_bib29","doi-asserted-by":"crossref","first-page":"103280","DOI":"10.1016\/j.critrevonc.2021.103280","article-title":"Neoadjuvant chemotherapy in hormone receptor-positive\/HER2-negative early breast cancer: when, why and what?","volume":"160","author":"Torrisi","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.surg.2026.110236_bib30","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1001\/jamaoncol.2016.1897","article-title":"Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis","volume":"2","author":"Spring","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.surg.2026.110236_bib31","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ejca.2022.07.028","article-title":"Pre-operative ribociclib plus letrozole versus chemotherapy: health-related quality of life outcomes from the SOLTI CORALLEEN trial","volume":"174","author":"Villacampa","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.surg.2026.110236_bib32","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41591-024-03415-7","article-title":"Pembrolizumab and chemotherapy in high-risk, early-stage, ER\/HER2 breast cancer: a randomized phase 3 trial","volume":"31","author":"Cardoso","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.surg.2026.110236_bib33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41523-023-00536-z","article-title":"Evaluation of multigene assays as predictors for response to neoadjuvant chemotherapy in early-stage breast cancer patients","volume":"9","author":"Freeman","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.surg.2026.110236_bib34","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.3390\/cancers17162706","article-title":"A priori prediction of breast cancer response to neoadjuvant chemotherapy using CT radiomics","volume":"17","author":"Jang","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.surg.2026.110236_bib35","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12880-024-01198-4","article-title":"Prediction of neoadjuvant chemotherapy pathological complete response for breast cancer based on radiomics nomogram of intratumoral and derived tissue","volume":"24","author":"Zheng","year":"2024","journal-title":"BMC Med Imaging"},{"key":"10.1016\/j.surg.2026.110236_bib36","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1186\/s12916-023-03163-4","article-title":"Construction of a risk stratification model integrating ctDNA to predict response and survival in neoadjuvant-treated breast cancer","volume":"21","author":"Liu","year":"2023","journal-title":"BMC Med"}],"container-title":["Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039606026001613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039606026001613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:33:50Z","timestamp":1794476030000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039606026001613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":36,"alternative-id":["S0039606026001613"],"URL":"https:\/\/doi.org\/10.1016\/j.surg.2026.110236","relation":{},"ISSN":["0039-6060"],"issn-type":[{"value":"0039-6060","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival outcomes after neoadjuvant chemotherapy in hormone receptor\u2013positive breast cancer patients with nodal metastases: A National Cancer Database analysis","name":"articletitle","label":"Article Title"},{"value":"Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.surg.2026.110236","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110236"}}